New drugs for atrial fibrillation

Journal of Interventional Cardiac Electrophysiology

Volumn 23, Issue 1, 2008, Pages 15-21

  Hammwöhner, Matthias ^a   Smid, Jan ^a   Lendeckel, Uwe ^a   Goette, Andreas ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

Atrial fibrillation; Drugs; Pathophysiology; Pharmacology; Therapy

Indexed keywords

2 [7 [3 (4 CYANOPHENOXY) 2 HYDROXYPROPYL] 9 OXA 3,7 DIAZABICYCLO[3.3.1]NON 3 YL]ETHYLCARBAMIC ACID TERT BUTYL ESTER; 2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; 4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; ALDOSTERONE; ALPHA TOCOPHEROL; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; APIXABAN; ASCORBIC ACID; ATORVASTATIN; AVE 1231; C 9356; CANDESARTAN; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; DRONEDARONE; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUTILIDE; METHYLPREDNISOLONE; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; NIPI 142; NIPI 42; PLACEBO; PROPAFENONE; RIVAROXABAN; ROTIGAPTIDE; S 0100176; S 20951; S 9947; SPIRONOLACTONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERNAKALANT;

ANTIARRHYTHMIC ACTIVITY; ANTICOAGULANT THERAPY; CARDIOVERSION; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG WITHDRAWAL; GAP JUNCTION; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART ATRIUM THROMBOSIS; HEART MUSCLE FIBROSIS; HEART PROTECTION; HUMAN; INCIDENCE; LOW DRUG DOSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SECONDARY PREVENTION; THROMBOGENESIS; TISSUE REGENERATION; VITAMIN SUPPLEMENTATION;

ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS;

EID: 53949111163     PISSN: 1383875X     EISSN: 15728595     Source Type: Journal    
DOI: 10.1007/s10840-008-9278-2     Document Type: Review

References (46)

1. V. Fuster L. E. Ryden D. S. Cannom H. J. Crijns A. B. Curtis K. A. Ellenbogen 2006 ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Circulation 114 e257 e354
2. W. B. Kannel R. D. Abbott D. D. Savage P. M. McNamara 1982 Epidemiologic features of chronic atrial fibrillation: The Framingham study New England Journal of Medicine 306 1018 1022
3. U. Ravens E. Wettwer U. Schotten R. Wessel D. Dobrev 2006 [New antiarrhythmic drugs for therapy of atrial fibrillation: I. Ion channel blockers] Herzschrittmachertherapie & Elektrophysiologie 17 64 72
4. R. F. Bosch S. Nattel 2002 Cellular electrophysiology of atrial fibrillation Cardiovascular Research 54 259 269
5. S. de Haan M. Greiser E. Harks Y. Blaauw A. van Hunnik S. Verheule 2006 AVE0118, blocker of the transient outward current (I(to)) and ultrarapid delayed rectifier current (I(Kur)), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat Circulation 114 1234 1242
6. Y. Blaauw U. Schotten H. A. van H. R. Neuberger M. A. Allessie 2007 Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat Cardiovascular Research 75 89 98
7. L. Lofberg I. Jacobson L. Carlsson 2006 Electrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: A comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro Europace 8 549 557
8. R. N. Goldstein C. Khrestian L. Carlsson A. L. Waldo 2004 Azd7009: A new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model Journal of Cardiovascular Electrophysiology 15 1444 1450
9. H. Gogelein J. Brendel K. Steinmeyer C. Strubing N. Picard D. Rampe 2004 Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels Naunyn-Schmiedeberg's Archives of Pharmacology 370 183 192
10. K. J. Wirth J. Brendel K. Steinmeyer D. K. Linz H. Rutten H. Gogelein 2007 In vitro and in vivo effects of the atrial selective antiarrhythmic compound AVE1231 Journal of Cardiovascular Pharmacology 49 197 206
11. D. Roy B. H. Rowe I. G. Stiell B. Coutu J. H. Ip D. Phaneuf 2004 A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation Journal of the American College of Cardiology 44 2355 2361
12. P. Touboul J. Brugada A. Capucci H. J. Crijns N. Edvardsson S. H. Hohnloser 2003 Dronedarone for prevention of atrial fibrillation: A dose-ranging study European Heart Journal 24 1481 1487
13. J. Ausma M. Wijffels F. Thone L. Wouters M. Allessie M. Borgers 1997 Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat Circulation 96 3157 3163
14. A. Frustaci C. Chimenti F. Bellocci E. Morgante M. A. Russo A. Maseri 1997 Histological substrate of atrial biopsies in patients with lone atrial fibrillation Circulation 96 1180 1184
15. A. Goette G. Juenemann B. Peters H. U. Klein A. Roessner C. Huth 2002 Determinants and consequences of atrial fibrosis in patients undergoing open heart surgery Cardiovascular Research 54 390 396
16. A. Goette U. Lendeckel 2004 Nonchannel drug targets in atrial fibrillation Pharmacology & Therapeutics 102 17 36
17. S. Nattel 2002 New ideas about atrial fibrillation 50 years on Nature 415 219 226
18. A. L. Kjolbye C. B. Knudsen T. Jepsen B. D. Larsen J. S. Petersen 2003 Pharmacological characterization of the new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2 (ZP123): In vivo and in vitro studies Journal of Pharmacology and Experimental Therapeutics 306 1191 1199
19. S. Aonuma Y. Kohama K. Akai Y. Komiyama S. Nakajima M. Wakabayashi 1980 Studies on heart. XIX. Isolation of an atrial peptide that improves the rhythmicity of cultured myocardial cell clusters Chemical and Pharmaceutical Bulletin (Tokyo) 28 3332 3339
20. B. C. Eloff E. Gilat X. Wan D. S. Rosenbaum 2003 Pharmacological modulation of cardiac gap junctions to enhance cardiac conduction: Evidence supporting a novel target for antiarrhythmic therapy Circulation 108 3157 3163
21. D. Xing A. L. Kjolbye M. S. Nielsen J. S. Petersen K. W. Harlow N. H. Holstein-Rathlou 2003 ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs Journal of Cardiovascular Electrophysiology 14 510 520
22. A. Shiroshita-Takeshita M. Sakabe K. Haugan J. K. Hennan S. Nattel 2007 Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs Circulation 115 310 318
23. J. A. Vest X. H. Wehrens S. R. Reiken S. E. Lehnart D. Dobrev P. Chandra 2005 Defective cardiac ryanodine receptor regulation during atrial fibrillation Circulation 111 2025 2032
24. K. Kumagai H. Nakashima N. Gondo K. Saku 2003 Antiarrhythmic effects of JTV-519, a novel cardioprotective drug, on atrial fibrillation/flutter in a canine sterile pericarditis model Journal of Cardiovascular Electrophysiology 14 880 884
25. C. A. Carnes M. K. Chung T. Nakayama H. Nakayama R. S. Baliga S. Piao 2001 Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation Circulation Research 89 E32 E38
26. S. C. Dudley Jr. N. E. Hoch L. A. McCann C. Honeycutt L. Diamandopoulos T. Fukai 2005 Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: Role of the NADPH and xanthine oxidases Circulation 112 1266 1273
27. M. J. Mihm F. Yu C. A. Carnes P. J. Reiser P. M. McCarthy D. R. Van Wagoner 2001 Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation Circulation 104 174 180
28. A. Shiroshita-Takeshita G. Schram J. Lavoie S. Nattel 2004 Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs Circulation 110 2313 2319
29. G. Patti M. Chello D. Candura V. Pasceri A. D'Ambrosio E. Covino 2006 Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study Circulation 114 1455 1461
30. J. Dernellis M. Panaretou 2004 Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation European Heart Journal 25 1100 1107
31. J. Halonen P. Halonen O. Jarvinen P. Taskinen T. Auvinen M. Tarkka 2007 Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: A randomized controlled trial JAMA 297 1562 1567
32. C. S. van der Hooft J. Heeringa G. G. Brusselle A. Hofman J. C. Witteman J. H. Kingma 2006 Corticosteroids and the risk of atrial fibrillation Archives of Internal Medicine 166 1016 1020
33. A. Goette T. Staack C. Rocken M. Arndt J. C. Geller C. Huth 2000 Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation Journal of the American College of Cardiology 35 1669 1677
34. A. Goette M. Arndt C. Rocken A. Spiess T. Staack J. C. Geller 2000 Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans Circulation 101 2678 2681
35. D. Li S. Fareh T. K. Leung S. Nattel 1999 Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different sort Circulation 100 87 95
36. K. Kumagai H. Nakashima H. Urata N. Gondo K. Arakawa K. Saku 2003 Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation Journal of the American College of Cardiology 41 2197 2204
37. A. Goette P. Hoffmanns W. Enayati U. Meltendorf J. C. Geller H. U. Klein 2001 Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation American Journal of Cardiology 88 906 909 A8
38. F. Zannad F. Alla B. Dousset A. Perez B. Pitt 2000 Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the randomized aldactone evaluation study (RALES). Rales investigators Circulation 102 2700 2706
39. A. Goette A. Bukowska U. Lendeckel M. Erxleben M. Hammwohner D. Strugala 2008 Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression Circulation 117 732 742
40. M. Hammwöhner A. Ittenson J. Dierkes A. Bukowska H. U. Klein U. Lendeckel 2007 Platelet expression of CD40/CD40 ligand and its relation to inflammatory markers and adhesion molecules in patients with atrial fibrillation Experimental Biology and Medicine (Maywood, N.J.) 232 581 589
41. B. I. Eriksson D. J. Quinlan 2006 Oral anticoagulants in development: Focus on thromboprophylaxis in patients undergoing orthopaedic surgery Drugs 66 1411 1429
42. J. I. Weitz S. M. Bates 2005 New anticoagulants Journal of Thrombosis and Haemostasis 3 1843 1853
43. M. Hammwöhner A. D'Alessandro O. Wolfram A. Goette 2007 New pharmacologic approaches to prevent thromboembolism in patients with atrial fibrillation Current Vascular Pharmacology 5 211 219
44. M. Hammwöhner A. D'Alessandro D. Dobrev P. Kirchhof A. Goette 2006 [New antiarrhythmic drugs for therapy of atrial fibrillation: II. Non-ion channel blockers] Herzschrittmachertherapie & Elektrophysiologie 17 73 80
45. A. Goette A. Bukowska U. Lendeckel 2007 Non-ion channel blockers as anti-arrhythmic drugs (reversal of structural remodeling) Current Opinion in Pharmacology 7 219 224
46. D. M. Monroe M. Hoffman H. R. Roberts 2002 Platelets and thrombin generation Arteriosclerosis, Thrombosis, and Vascular Biology 22 1381 1389